Drug Trial Radar · NCT06731764
Novel Approaches to the Treatment of Hypothyroidism
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Dec 10, 2024
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- UConn HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism. To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine/liothyronine combination therapy.
Conditions
- Hypothyroidism
Interventions
LevothyroxineDrug
Patients will receive Levothyroxine/Placebo Levothyroxine/Liothyronine with Liothyronine administered twice daily.
Levothyroxine/Liothyronine once dailyDrug
Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
Levothyroxine/Liothyronine twice dailyDrug
Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Total CholesterolTime frame: 6 month
- Changes in LDL CholesterolTime frame: 6 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UConn Health
Farmington, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.